Gisadenafil (UK-369003) is a novel, oral and potent phosphodiesterase PDE5 inhibitor being developed by Pfizer for the treatment of overactive bladder and for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder. It is 80 fold selective over PDE6, and greater than 3000 fold selective over PDEs 1-4 and 7.

纯度：≥98%

CAS：334826-98-1